Cumberland Pharmaceuticals Higher; Drug Update Slated for Oct. 26
Dow Jones10-21
Cumberland Pharmaceuticals shares were higher after a brief announcement related to a drug candidate.
The stock rose 18% to $7.92 Tuesday and is up about 99% this year.
The company said Monday that it will provide an update Oct. 26 about ifetroban, in development as a potential treatment for cardiomyopathy associated with Duchenne muscular dystrophy. A webcast and conference call is scheduled for 4:30 p.m. ET on that date.
On June 26, Cumberland reported updated results from a Phase 2 ifetroban trial. It said additional cardiac biomarker analyses further demonstrated ifetroban's cardioprotective effect.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments